Mounjaro is Tirzepatide, a dual GIP and GLP-1 agonist with a different mechanism and often greater average weight loss in trials
Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant Astrocytomas
Settanni CR, Bibb S, Ianiro G, Rinninella E, Cintoni M, Mele MC, Cammarota G, Gasbarrini A (2021) Gastrointestinal involvement of autism spectrum disorder: focus on gut microbiota
These results exceeded what has been observed with current market-leading medications, including tirzepatide, which typically produces weight loss of around 15-21% in clinical settings
R.NauckM
The product is also gaining widespread use in intravenous therapies for medical and aesthetic purposes, adding to its prominence in clinical and consumer markets alike